Thinking of joining a study?

Register your interest

NCT06837272 | RECRUITING | Alzheimer Disease


A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease
Sponsor:

Jining Medical University

Information provided by (Responsible Party):

Can Sheng

Brief Summary:

Gut microbiota dysfunction is associated with Alzheimer's disease (AD). However, the potential modulatory mechanism remains unclear. Previous studies have shown that gut-derived metabolites short-chain fatty acids (SCFAs) may be the key mediators between gut microbiota and brain, participating in the modulatory pathway "gut microbiota-SCFAs-brain networks". In this project, high-throughput targeted metabolomics technique will be used to explore the differences of SCFAs in the spectrum of AD, including cognitively normal individuals, subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD dementia. Then, the gut microbiome and multi-modal MRI techniques will be combined to elucidate potential interaction mechanisms of "gut microbiota-SCFAs-brain networks". Finally, based on multi-omics features extracted from gut microbiome, metabolomics, and neuroimaging after five years, the diagnostic model of SCD due to preclinical AD will be established using machine learning methods.

Condition or disease

Alzheimer Disease

Gut Microbiota

Metabonomics

Magnetic Resonance Imaging

Intervention/treatment

Multi-omics features extraction

Study Type : OBSERVATIONAL
Estimated Enrollment : 285 participants
Official Title : A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease: China Healthy Brain and Gut Microbiome Study (CHBGMS)
Actual Study Start Date : 2024-01-01
Estimated Primary Completion Date : 2026-12-31
Estimated Study Completion Date : 2029-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 60 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • * Cognitively normal group
    • 1. normal performance on standardized cognitive tests;
    • 2. with no cognitive complaints or any concerns (worries).
    • * SCD group
      • 1. self-experienced persistent decline in memory, rather than other domains of cognition;
      • 2. normal performance on standardized cognitive tests;
      • 3. failure to meet the criteria for MCI or dementia;
      • 4. age at onset of SCD ≥ 60 years old;
      • 5. onset of SCD within the last 5 years;
      • 6. concerns (worries) associated with SCD;
      • 7. feeling of worse performance than others of the same age group.
      • * MCI group
        • 1. having impaired scores on both measures in at least one cognitive domain (memory, language, or speed/executive function);
        • 2. having impaired scores in each of the three cognitive domains (memory, language, or speed/executive function);
        • 3. the Functional Activities Questionnaire (FAQ)≥9.
        • * AD dementia group
          • 1. meet the criteria for dementia and have impaired daily functional activities;
          • 2. episodic memory deficit; 3) Clinical Dementia Rating (CDR) ≥ 1.
          Exclusion Criteria
          • * a history of stroke;
          • * major depression and anxiety;
          • * other central nervous system disorders that may cause cognitive impairment, such as Parkinson's disease, tumors, encephalitis, and epilepsy;
          • * cognitive impairment caused by traumatic brain injury;
          • * systemic diseases, such as thyroid dysfunction, syphilis and HIV;
          • * psychosis or congenital mental developmental delay;
          • * a history of using antibiotics, probiotics, prebiotics, or synbiotics within 3 months;
          • * the use of corticosteroid, immune stimulating medications, and immunosuppressive agents;
          • * major gastrointestinal tract surgery in past 5 years;
          • * severe gastrointestinal diseases, such as irritable bowel syndrome, infammatory bowel disease, severe gastritis, other dysfunction in digestion and absorption, which has been reported to infuence gut microbiota

A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease

Location Details

NCT06837272


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

China, Shandong

Department of Neurolgy, the Affiliated Hospital of Jining Medical University

jin ing, Shandong, China, 272029

Loading...